Odyssey Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Odyssey Therapeutics, Inc. Common Stock (ODTX) has an Asset Resilience Ratio of 47.23% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Odyssey Therapeutics, Inc. Common Stock debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Odyssey Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. See financial flexibility index of Odyssey Therapeutics, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Odyssey Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Odyssey Therapeutics, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $228.54 Million | 47.23% |
| Total Liquid Assets | $228.54 Million | 47.23% |
Asset Resilience Insights
- Very High Liquidity: Odyssey Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 47.23% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Odyssey Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Odyssey Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Seegene Inc
KQ:096530 |
Biotechnology | 24.96% |
Annual Asset Resilience Ratio for Odyssey Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Odyssey Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 51.77% | $139.67 Million | $269.79 Million | +16.21pp |
| 2024-12-31 | 35.57% | $70.22 Million | $197.44 Million | -11.36pp |
| 2023-12-31 | 46.93% | $134.45 Million | $286.52 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $317.15 Million | -- |
About Odyssey Therapeutics, Inc. Common Stock
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated … Read more